SCOPUS 정보 검색 플랫폼

Nature Biotechnology

Volumn 34, Issue 7, 2016, Pages 706-708

Plant specific N-glycans do not have proven adverse effects in humans

(2) Shaaltiel, Yoseph a Tekoah, Yoram a

a Protalix Biotherapeutics (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCAN; IMIGLUCERASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; TALIGLUCERASE ALFA; VEGETABLE PROTEIN; VELAGLUCERASE ALFA; POLYSACCHARIDE;

ADVERSE DRUG REACTION; ALLERGENICITY; ANAPHYLAXIS; HUMAN; HYPERSENSITIVITY; IMMUNOGENICITY; LETTER; NONHUMAN; PLANT PRODUCT; PLANT SEED; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; CARBOHYDRATE ANALYSIS; PLANT;

CARBOHYDRATE SEQUENCE; HUMANS; PLANTS; POLYSACCHARIDES;

EID: 84978290995 PISSN: 10870156 EISSN: 15461696 Source Type: Journal
DOI: 10.1038/nbt.3556 Document Type: Letter

Times cited : (55)

References (13)

1
- 84947233184
- Piron, R., Santens, F., De Paepe, A., Depicker, A., Callewaert, N. Nat. Biotechnol. 33, 1135-1137 (2015).
- (2015) Nat. Biotechnol , vol.33 , pp. 1135-1137
- Piron, R.¹ Santens, F.² De Paepe, A.³ Depicker, A.⁴ Callewaert, N.⁵

2
- 84900323466
- Meuris, L. et al. Nat. Biotechnol. 32, 485-489 (2014).
- (2014) Nat Biotechnol , vol.32 , pp. 485-489
- Meuris, L.¹

3
- 0038581900
- Bardor, M. et al. Glycobiol. 13, 427-434 (2003).
- (2003) Glycobiol , vol.13 , pp. 427-434
- Bardor, M.¹

4
- 78650981716
- Landry, N. et al. PLoS One 5, e15559 (2010).
- (2010) PLoS One , vol.5 , pp. e15559
- Landry, N.¹

5
- 84908003879
- Ward, B.J. et al. Vaccine 32, 6098-6106 (2014).
- (2014) Vaccine , vol.32 , pp. 6098-6106
- Ward, B.J.¹

6
- 84894556937
- US Food and Drug Administration FDA, July
- US Food and Drug Administration. Guidance for Industry, Safety Labeling Changes-Implementation of Section 505(o)(4) of the FD&C Act. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinf ormation/guidances/ucm250783.pdf (FDA, July 2013).
- (2013) Guidance for Industry Safety Labeling Changes-Implementation of Section 505(o)(4) of the FD&CAct

7
- 84942193222
- Tekoah, Y. et al. Plant Biotechnol. J. 13, 1199-1208 (2015).
- (2015) Plant Biotechnol. J , vol.13 , pp. 1199-1208
- Tekoah, Y.¹

8
- 84978270488
- US Food and Drug Administration
- US Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022458s003s006lbl.pdf (2014).
- (2014)

9
- 84958777568
- Broomfield, A., Jones, S.A., Hughes, S.M., Bigger, B. W. J. Inherit. Metab. Dis. doi:10.1007/s10545-016-9917-1 (2016).
- (2016) Inherit. Metab. Dis
- Broomfield, A.¹ Jones, S.A.² Hughes, S.M.³ Bigger, B.W.J.⁴

10
- 84978270493
- US Food and Drug Administration FDA March
- US Food and Drug Administration. Cerezyme (imiglucerase for injection): proposed text of the labeling of the drug. http://www.accessdata.fda.gov/drugsatfda-docs/label/2005/20367s066lbl.pdf (FDA, March 2003).
- (2003) Cerezyme (Imiglucerase for Injection): Proposed Text of the Labeling of the Drug

11
- 79960720836
- US Food and Drug Administration FDA April
- US Food and Drug Administration. Highlights of prescribing information for VPRIV. http://www.accessdata. fda.gov/drugsatfda-docs/label/2015/022575s017lbl. pdf (FDA, April 2015).
- (2015) Highlights of Prescribing Information for VPRIV

12
- 84978214215
- European Medicines Agency European public assessment report (EPAR) summary for the public for Cerezyme
- European Medicines Agency. European public assessment report (EPAR) summary for the public for Cerezyme. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/000157/WC500024108.pdf

13
- 84879307489
- Bosch, D., Castilho, A., Loos, A., Schots, A., Steinkellner, H. Curr. Pharm. Des. 19, 5503-5512 (2013).
- (2013) Curr. Pharm. des , vol.19 , pp. 5503-5512
- Bosch, D.¹ Castilho, A.² Loos, A.³ Schots, A.⁴ Steinkellner, H.⁵

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.